Literature DB >> 33534082

Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study.

Lei Liang1,2, Bing Quan3, Han Wu4, Yong-Kang Diao1,2, Jie Li5, Ting-Hao Chen6, Yao-Ming Zhang7, Ya-Hao Zhou8, Wan-Guang Zhang9, Hong Wang10, Matteo Serenari11, Matteo Cescon11, Myron Schwartz12, Yong-Yi Zeng13, Ying-Jian Liang14, Hang-Dong Jia1,2, Hao Xing4, Chao Li4, Ming-Da Wang4, Wen-Tao Yan3, Wan-Yuan Chen15, Wan Yee Lau4,16, Cheng-Wu Zhang1, Timothy M Pawlik17, Dong-Sheng Huang18,19, Feng Shen4, Tian Yang20,21,22.   

Abstract

BACKGROUND: Evidence-based decision-making is critical to optimize the benefits and mitigate futility associated with surgery for patients with malignancies. Untreated hepatocellular carcinoma (HCC) has a median survival of only 6 months. The objective was to develop and validate an individualized patient-specific tool to predict preoperatively the benefit of surgery to provide a survival benefit of at least 6 months following resection.
METHODS: Using an international multicenter database, patients who underwent curative-intent liver resection for HCC from 2008 to 2017 were identified. Using random assignment, two-thirds of patients were assigned to a training cohort with the remaining one-third assigned to the validation cohort. Independent predictors of postoperative death within 6 months after surgery for HCC were identified and used to construct a nomogram model with a corresponding online calculator. The predictive accuracy of the calculator was assessed using C-index and calibration curves.
RESULTS: Independent factors associated with death within 6 months of surgery included age, Child-Pugh grading, portal hypertension, alpha-fetoprotein level, tumor rupture, tumor size, tumor number and gross vascular invasion. A nomogram that incorporated these factors demonstrated excellent calibration and good performance in both the training and validation cohorts (C-indexes: 0.802 and 0.798). The nomogram also performed better than four other commonly-used HCC staging systems (C-indexes: 0.800 vs. 0.542-0.748).
CONCLUSIONS: An easy-to-use online prediction calculator was able to identify patients at highest risk of death within 6 months of surgery for HCC. The proposed online calculator may help guide surgical decision-making to avoid futile surgery for patients with HCC.

Entities:  

Keywords:  Calculator; Hepatocellular carcinoma; Liver resection; Mortality; Multicenter; Nomogram; Postoperative; Prediction; Surgery; Survival

Year:  2021        PMID: 33534082     DOI: 10.1007/s12072-021-10140-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  39 in total

Review 1.  Collective wisdom and decision making in surgical oncology.

Authors:  N Robson; D Rew
Journal:  Eur J Surg Oncol       Date:  2010-01-27       Impact factor: 4.424

Review 2.  Localized and systemic approaches to treating hepatocellular carcinoma.

Authors:  Jennifer J Knox; Sean P Cleary; Laura A Dawson
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 3.  Hepatocellular carcinoma: A global view.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-13       Impact factor: 46.802

Review 4.  Regret in Surgical Decision Making: A Systematic Review of Patient and Physician Perspectives.

Authors:  Ana Wilson; Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

Review 5.  Hepatocellular carcinoma: current management and perspectives for the future.

Authors:  Nuh N Rahbari; Arianeb Mehrabi; Nathan M Mollberg; Sascha A Müller; Moritz Koch; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

6.  Decision making in surgical oncology.

Authors:  B Lamb; J S A Green; C Vincent; N Sevdalis
Journal:  Surg Oncol       Date:  2010-08-16       Impact factor: 3.279

7.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

8.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.

Authors:  K Okuda; T Ohtsuki; H Obata; M Tomimatsu; N Okazaki; H Hasegawa; Y Nakajima; K Ohnishi
Journal:  Cancer       Date:  1985-08-15       Impact factor: 6.860

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  The natural history of hepatocellular carcinoma. A study of 100 untreated cases.

Authors:  N Nagasue; H Yukaya; T Hamada; S Hirose; R Kanashima; K Inokuchi
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.